Biogen | Gastos De Venta Y Administración



Selling And Administration Expenses Cambio Fecha
AbbVie USD 3.86B 306M 2024-12
Acadia Pharmaceuticals USD 130.08M 3.21M 2024-12
ALKERMES USD 146.99M 3.39M 2024-12
Amgen USD 1.88B 253M 2024-12
Bayer EUR 4.34B 610M 2024-12
Biogen USD 677.3M 99.6M 2024-12
BioMarin Pharmaceutical USD 256.77M 46.81M 2024-12
Bristol-Myers Squibb USD 2.1B 129M 2024-12
Eli Lilly USD 2.42B 324.7M 2024-12
Gilead Sciences USD 1.86B 451M 2024-12
Incyte USD 326.71M 17.5M 2024-12
Intra Cellular Therapies USD 137.73M 5.63M 2024-12
Merck USD 2.85B 148M 2024-12
Moderna USD 351M 70M 2024-12
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Novartis USD 3.5B 368M 2024-12
Pfizer USD 4.27B 1.06B 2024-12
PTC Therapeutics USD 84.68M 11.23M 2024-12
Regeneron Pharmaceuticals USD 792.2M 77.8M 2024-12
Sanofi EUR 2.68B 26M 2024-09
Sanofi EUR 2.68B 26M 2024-09
Sarepta Therapeutics USD 163.87M 35.67M 2024-12
Teva Pharmaceutical Industries USD 952M 28M 2024-12
Ultragenyx Pharmaceutical USD 82.49M 2.14M 2024-12
United Therapeutics USD 162.5M 8.4M 2024-12
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12



Biogen Gastos De Venta Y Administración - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.